Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 3/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18014799 | 0.85 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18540667 | 0.82 | GPR84 (0.35) | HTR2AHTR2CHTR2BGPR84HTR1D | |
| SCHEMBL16729582 | 0.79 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22822514 | 0.72 | HTR1D (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13360743 | 0.70 | PDE2A (0.42) | PDE2A | |
| SCHEMBL12596196 | 0.69 | ADRB2 (0.38) | HTR2AHTR2CHTR2BGPR84HTR1D | |
| SCHEMBL18015901 | 0.67 | HTR1D (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5415312 | 0.65 | GABRA1 (0.46) | P2RX7 | |
| SCHEMBL4552632 | 0.65 | CMA1 (0.52) | CMA1HTR2AHTR2CHTR2BGPR84 | |
| SCHEMBL18508879 | 0.64 | KDM4E (0.58) | GPR84HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
| WO-2015049616-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | PSEN1 4/4885PSEN2 3/4885APH1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.